ARGENX SE

argenx SE filed a Form 6-K report with the U.S. Securities and Exchange Commission for the month of August 2026. This filing incorporates by reference a press release issued on August 27, 2026. The information within this report is deemed to be incorporated into the Company's existing Registration Statements on Forms S-8.

argenx, through its wholly-owned subsidiary Avena Merger Sub Inc., has commenced a tender offer to acquire all outstanding shares of Forte Biosciences, Inc. for $77.00 per share in cash. The offer is made under a merger agreement dated July 26, 2026, and Forte's Board of Directors has recommended that its stockholders accept the offer. The tender offer is set to expire on August 26, 2026, and is subject to customary conditions, including a minimum tender condition.

argenx SE announced an Extraordinary General Meeting of Shareholders (EGM) to be held on Thursday, September 17, 2026, at 15:00 CEST in Amsterdam. The primary agenda for the EGM includes voting on the proposed appointments of Mr. Thomas M. Brakel and Mr. Khurem Farooq as non-executive directors to the Company’s Board of Directors. Shareholders are encouraged to utilize the voting by (electronic) proxy option.

argenx announced a definitive agreement to acquire Forte Biosciences for approximately $2.2 billion, paying $77 per share in cash. This acquisition, representing an 86% premium, strengthens argenx's immunology portfolio by adding FB102, Forte Biosciences' lead anti-CD122 antibody program. FB102 has shown clinical proof-of-concept in vitiligo and celiac disease, with potential for other autoimmune conditions, aligning with argenx's strategy to address diseases with unmet needs. The transaction is expected to close in the third quarter of 2026.

argenx SE reported strong financial results for the second quarter and half-year 2026, driven by robust sales of VYVGART. Global product net sales for Q2 reached $1.5 billion, marking a 60% year-over-year growth, while half-year sales hit $2.8 billion. The company successfully launched VYVGART and VYVGART Hytrulo for all generalized myasthenia gravis (gMG) serotypes, significantly expanding its market opportunity. Key pipeline milestones are also on track, with registrational study readouts for autoimmune myositis expected in Q3 2026 and for multifocal motor neuropathy (MMN) in Q4 2026.

argenx SE reported strong second-quarter 2026 results with global product net sales of $1.5 billion, marking a 60% year-over-year and 17% quarter-over-quarter growth. The company successfully launched an expanded label for VYVGART and VYVGART Hytrulo to include all gMG serotypes, broadening patient reach. Key registrational study readouts for autoimmune myositis and multifocal motor neuropathy (MMN) are on track for Q3 and Q4 2026, respectively, supporting pipeline expansion. The company also reported a significant increase in operating profit and profit for the period.

Argenx announced it will host a conference call and audio webcast on Thursday, July 23, 2026, at 2:30 p.m. CET (8:30 a.m. ET). The call will cover the company's half-year 2026 financial results and provide a second-quarter business update. Investors can access the live webcast on the company's website or join via provided dial-in numbers.

Argenx, a global immunology company, announced it will host an R&D webinar today, June 23, 2026, at 2:00 PM ET. The webinar, titled "R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis," will feature argenx management and scientific leadership alongside external key opinion leaders. A live webcast and supporting presentation slides will be available on the company's investor relations website.

Argenx presented new efgartigimod data at EULAR 2026, demonstrating long-term sustained patient benefit and a consistent safety profile in myositis and Sjogren's disease. The ALKIVIA+ open-label extension study showed sustained clinically meaningful improvements in myositis patients, with 37.5% maintaining major TIS improvement at 52 weeks. The RHO+ study indicated maintenance of response in Sjogren's disease patients following a switch to biweekly dosing, with low median ClinESSDAI scores at Week 72. A cross-indication safety analysis reinforced efgartigimod's well-tolerated profile across multiple autoimmune rheumatic diseases.

Argenx announced new data at EULAR 2026 for efgartigimod in autoimmune rheumatic diseases, including myositis and Sjogren's disease. The ALKIVIA+ open-label extension study in myositis showed sustained, clinically meaningful improvements and a consistent safety profile through 52 weeks. The RHO+ open-label extension study in Sjogren's disease indicated maintenance of response following a switch to biweekly dosing. A cross-indication analysis reinforced efgartigimod's consistent safety profile across a large patient population.